BOSTON
Strategia Holdings, LLC. announced a strategic partnership alliance with JS InnoPharm (Shanghai), Ltd. to facilitate global drug development. Through this partnership, both companies will leverage their comprehensive knowledge, broad expertise, drug candidates, and networks in the global development of multiple therapeutics.
“We are very excited about this strategic partnership with JS InnoPharm in Shanghai. By combining the strengths of JS InnoPharm with their drug discovery expertise and China network to Strategia Holdings, LLC, we are creating a new, efficient, streamlined model for global drug development,” said Dr. Keizo Koya, CEO and Founder of Strategia. “This is an innovative and unique collaboration that will translate the highest-quality science into proven clinical success in an efficient and agile manner while enhancing the competitive position of both companies in the ever-increasing challenging environment of clinical drug development. The ultimate goal of this partnership is to effectively deliver new therapeutic approaches to patients worldwide.”
The Strategia Holdings group currently consists of three biopharmaceutical companies; Spirita Oncology, LLC, Mirata BioPharma, LLC, and Strategia Pharmaceuticals, LLC. All three organizations will work closely together with JS InnoPharm under the Strategic Partnership Alliance.
“JS InnoPharm is keen on collaborating with Strategia to establish long-term commitments to accelerate global drug development with us,” said Dr. Jintao Zhang, CEO of JS InnoPharm. “We believe in the power of China and the US coming together and crafting solutions to enhance efficiencies and achieve faster drug development timelines with higher success rates. This partnership allows the organizations to work closely together in a collaborative effort to reach those goals.”
About Strategia
Strategia Holdings, LLC, is based in the U.S. and oversees three biotech companies; Spirita Oncology, LLC, Mirata BioPharma, LLC, and Strategia Pharmaceuticals, LLC. Spirita focuses on oncology drug development in the US with E6201, a MEK1 inhibitor, as their flagship candidate focused on melanoma brain metastases. Mirata is a pre-clinical stage immuno-oncology company based on a Targeted Granzyme B Immunotherapy (TGI) platform. Strategia Pharmaceuticals was established in 2012 consisting of oncology pharma and biotech drug development veterans, and is a strategic consulting company to assist pharma and biotech clients develop their oncology portfolios with greater expertise, more efficiently, more rapidly, translating into lower overall cost to market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180826005031/en/
CONTACT
MEDIA:
Strategia Holdings, LLC
Mito Aoki Koya
General
Manager
contact@strategiatx.com
Website:
www.strategiatx.com
